NCT00002274已完成不适用
An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir)
Bristol-Myers Squibb1 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 1
研究概览
简要总结
The objective of this open-label study regimen is to make didanosine (ddI) available to patients with AIDS who are clinically deteriorating on zidovudine (AZT) and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Concurrent medications for treatment of complications of AIDS are allowed.
- •Aerosolized pentamidine.
- •Phenytoin, but with caution.
- •Extreme caution should be exercised in the use of didanosine (ddI) in any patient receiving concurrent therapies, particularly those receiving other nucleosides (e.g., ganciclovir), drugs with toxicities similar to those observed with ddI (list included under concomitant medications section of protocol), and other drugs with significant toxicities, including many drugs used for treatment of major opportunistic infections.
- •Patients must be:
- •- Not suitable for entry into ddI phase II studies by reason of inclusion or
排除标准
- •or by reason of geographic location.
- •Able to provide signed informed consent (parent/guardian as appropriate). Available for monthly follow-up while taking ddI. Meet required baseline laboratory values within 14 days prior to initial drug dosing.
- •Extreme caution should be exercised in the use of ddI in any patient receiving concomitant therapies, particularly those receiving other nucleosides (e.g., ganciclovir), drugs with toxicities similar to those observed with ddI (list included under concomitant medications section of protocol), and other drugs with significant toxicities, including many drugs used for treatment of major opportunistic infections.
- •Caution should also be exercised in a patient having intractable diarrhea or patients following a low-sodium diet. Physicians caring for these patients must perform clinical and laboratory evaluations every 7-10 days for the first 2 months of ddI therapy. Should any adverse effect of any severity be detected during this period of intensive clinical and laboratory monitoring, the physician must call Bristol-Myers Squibb (1-800-662-7999). If the patient continues ddI therapy, Bristol-Myers Squibb will require submission of follow-up and adverse experience report forms every 10 days. Although data are not available to fully assess the risks associated with the use of ddI in high-risk patients (for example, patients with preexisting disorders of body systems known to be adversely affected by ddI, particularly those with history of peripheral neuropathy, pancreatitis, seizure disorder, cardiac abnormalities, gout, and significant elevations of liver function test results), all such patients must have clinical and laboratory evaluations performed every 10 days and results submitted to Bristol-Myers Squibb on the case report forms provided.
- •Exclusion Criteria
- •Co-existing Condition:
- •Patients with any one of the following criteria are excluded:
- •Received therapy in the preceding 15 days with any other antiretroviral except zidovudine (AZT).
- •Taking AZT concomitantly.
- •Acute pancreatitis.
- •Poorly controlled seizure disorder.
- •Taking phenytoin concomitantly.
- •Grade B or greater peripheral neuropathy.
- •Concurrent Medication:
- •Zidovudine (AZT).
- •Patients with any one of the following criteria are excluded:
- •Received therapy in the preceding 15 days with any other antiretroviral except zidovudine (AZT).
- •Taking AZT concomitantly.
- •Taking phenytoin concomitantly.
- •Acute pancreatitis.
- •Poorly controlled seizure disorder.
- •Grade B or greater peripheral neuropathy.
- •Prior Medication:
- •Excluded within 15 days of study entry:
- •Any antiretroviral except zidovudine (AZT).
- •Zidovudine (AZT).
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study of ddI in Children With AIDS Who Have Not Had Success With ZidovudineHIV InfectionsNCT00002280Bristol-Myers Squibb
已完成
不适用
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)HIV InfectionsNCT00002028Bristol-Myers Squibb
已完成
2 期
Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV PatientsHIV InfectionsNCT00007202National Institute of Allergy and Infectious Diseases (NIAID)55
已完成
2 期
One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose NevirapineHIV InfectionsNCT00142337Institut de Recherche pour le Developpement244
终止
2 期
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsHIV InfectionsNCT00002420Bristol-Myers Squibb25